Last Updated : July 11, 2024
Details
Generic Name:
cariprazine
Project Status:
Active
Therapeutic Area:
Schizophrenia
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0827-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Nov-23 |
|---|---|
| Call for patient/clinician input closed | 08-Jan-24 |
| Clarification: - Patient input submission received from Schizophrenia Society of Canada | |
| Submission received | 20-Dec-23 |
| Submission accepted | 11-Jan-24 |
| Review initiated | 12-Jan-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 08-Apr-24 |
| Deadline for sponsors comments | 17-Apr-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 09-May-24 |
| Expert committee meeting (initial) | 22-May-24 |
| Clarification: Recommendation deferred to June 26, 2024 CDEC meeting | |
| Draft recommendation issued to sponsor | 10-Jul-24 |
| Draft recommendation posted for stakeholder feedback | 18-Jul-24 |
| End of feedback period | 01-Aug-24 |
Last Updated : July 11, 2024